GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC
12 Janvier 2018 - 5:46PM
GENFIT: HALF-YEAR
REPORT OF LIQUIDITY CONTRACT WITH CIC
Lille (France),
Cambridge (Massachusetts, United States), January 12, 2018 -
GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical
company at the forefront of developing therapeutic and diagnostic
solutions in metabolic and inflammatory diseases, that notably
affect the liver or the gastrointestinal system, today announces
the half-year report of its liquidity contract with CIC.
Under the liquidity contract
granted to CIC by GENFIT, the following resources were in the
liquidity account as at Decembrer 31, 2017:
-
6,586 shares
-
€267,012.36 in cash.
At the half-year report as at June
30, 2017, the following resources were available in the liquidity
account:
-
3,753 shares
-
€254,255.05 in cash
Since the last communication on
the half year position of the liquidity contract at June 30, 2017,
GENFIT increased the amount allocated to the contract on December
8, 2017 by €250,000.
About
GENFIT
GENFIT is a biopharmaceutical
company focused on the discovery and development of drug candidates
in areas of high unmet medical needs corresponding to a lack of
suitable treatment and an increasing number of patients worldwide.
GENFIT's R&D efforts are focused on bringing new medicines to
market for patients with metabolic, inflammatory, autoimmune and
fibrotic diseases, that affect the liver (such as NASH -
Nonalcoholic steatohepatitis) and more generally the
gastro-intestinal arena. GENFIT's approach combines novel
treatments and biomarkers. Its lead proprietary compound,
elafibranor, is currently in a Phase 3 study. With facilities in
Lille and Paris, France, and Cambridge, MA (USA), the Company has
approximately 130 employees. GENFIT is a public company listed in
compartment B of Euronext's regulated market in Paris (Euronext:
GNFT - ISIN: FR0004163111). www.genfit.com
Forward Looking
Statement / Disclaimer
This press release contains certain forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking statements. These
risks and uncertainties include among other things, the
uncertainties inherent in research and development, including
related to biomarkers, progression of, and results of clinical data
from, the RESOLVE-IT trial and the trial of elafibranor in PBC,
review and approvals by regulatory authorities, such as the FDA or
the EMA, regarding in particular, elafibranor in NASH and PBC, as
well as other drug candidates in other indications and biomarkers
candidates, the success of any inlicensing strategies, the
Company's continued ability to raise capital to fund its
development, as well as those discussed or identified in the
Company's public filings with the AMF, including those listed in
Chapter 7 of the 2017 Half Year Business and Financial Report and
under Section 4 "Main Risks and Uncertainties" of the Company's
2016 Registration Document registered with the French Autorité des
marchés financiers on April 28, 2017 under n° R.17-034, which is
available on GENFIT's website (www.genfit.com) and on the website
of the AMF (www.amf-france.org). Other than as required by
applicable law, the Company does not undertake any obligation to
update or revise any forward-looking information or statements.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in GENFIT in any country. This press release
has been prepared in both French and English. In the event of any
differences between the two texts, the French language version
shall supersede.
CONTACT
GENFIT | Jean-François Mouney
- Chairman & CEO | +333 2016 4000
PRESS RELATIONS | Ulysse
communication - Bruno Arabian | +336 8788 4726
GENFIT | 885 Avenue Eugène
Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com
2018.01.12 PR GENFIT Half Year
report of Liquidity Contract
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GENFIT via Globenewswire
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024